EP3585420A4 - Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant - Google Patents

Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant Download PDF

Info

Publication number
EP3585420A4
EP3585420A4 EP18756867.0A EP18756867A EP3585420A4 EP 3585420 A4 EP3585420 A4 EP 3585420A4 EP 18756867 A EP18756867 A EP 18756867A EP 3585420 A4 EP3585420 A4 EP 3585420A4
Authority
EP
European Patent Office
Prior art keywords
peptides
methods
same
related disorders
dystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18756867.0A
Other languages
German (de)
English (en)
Other versions
EP3585420A2 (fr
Inventor
Eytan R. Barnea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioIncept LLC
Original Assignee
BioIncept LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioIncept LLC filed Critical BioIncept LLC
Priority to EP22150813.8A priority Critical patent/EP4066850A3/fr
Publication of EP3585420A2 publication Critical patent/EP3585420A2/fr
Publication of EP3585420A4 publication Critical patent/EP3585420A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18756867.0A 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant Withdrawn EP3585420A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22150813.8A EP4066850A3 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762462292P 2017-02-22 2017-02-22
PCT/US2018/019279 WO2018156801A2 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22150813.8A Division EP4066850A3 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Publications (2)

Publication Number Publication Date
EP3585420A2 EP3585420A2 (fr) 2020-01-01
EP3585420A4 true EP3585420A4 (fr) 2021-04-07

Family

ID=63253026

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18756867.0A Withdrawn EP3585420A4 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant
EP22150813.8A Withdrawn EP4066850A3 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22150813.8A Withdrawn EP4066850A3 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Country Status (6)

Country Link
EP (2) EP3585420A4 (fr)
CN (1) CN110869044A (fr)
AU (1) AU2018225163A1 (fr)
CA (1) CA3054366A1 (fr)
IL (1) IL268844A (fr)
WO (1) WO2018156801A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160263186A1 (en) * 2013-10-22 2016-09-15 Bioincept, Llc Pif-transfected cells and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454399T1 (de) 2001-07-02 2010-01-15 Bioincept Llc Assays für den präimplantationsfaktor und präimplantationsfaktorpeptide
US8222211B2 (en) 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US7723289B2 (en) 2003-10-22 2010-05-25 Bioincept, Llc PIF tetrapeptides
CA2927595C (fr) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
EP1793398A1 (fr) 2005-12-05 2007-06-06 Sokymat Automotive GmbH Dispositif de fixation pour und composant électronique et unité de fabrication avec table tournante
US7981860B2 (en) * 2006-03-13 2011-07-19 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
US8916532B2 (en) * 2008-04-28 2014-12-23 The Trustees Of The University Of Pennsylvania Methods for enhancing utrophin production via inhibition of microRNA
US8852940B2 (en) * 2009-04-01 2014-10-07 The Regents Of The University Of California Embryonic stem cell specific microRNAs promote induced pluripotency
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
DK2764140T3 (en) 2011-10-07 2017-12-04 Bicyclerd Ltd MODULATION OF STRUCTURED POLYPEPTIME SPECIFICITY
EP2819688A4 (fr) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Macrocycles peptidomimétiques réticulés par triazole et par thioéther
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
WO2014138429A2 (fr) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leur utilisation dans la régulation de hif1alpha
US20160250188A1 (en) * 2013-10-25 2016-09-01 Ernest D. Bush Methods for treatment of muscular dystrophies
IL295025A (en) * 2014-09-16 2022-09-01 Bioincept Llc Preparations and methods for the treatment of acute radiation syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160263186A1 (en) * 2013-10-22 2016-09-15 Bioincept, Llc Pif-transfected cells and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATRIZIA PESSINA ET AL: "Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy", SKELETAL MUSCLE, BIOMED CENTRAL LTD, LONDON, UK, vol. 4, no. 1, 25 August 2014 (2014-08-25), pages 7, XP021193544, ISSN: 2044-5040, DOI: 10.1186/2044-5040-4-7 *
UTPAL BASU ET AL: "Translational Regulation of Utrophin by miRNAs", PLOS ONE, vol. 6, no. 12, 27 December 2011 (2011-12-27), pages e29376, XP055751401, DOI: 10.1371/journal.pone.0029376 *

Also Published As

Publication number Publication date
AU2018225163A1 (en) 2019-09-19
WO2018156801A3 (fr) 2019-02-21
IL268844A (en) 2019-10-31
CA3054366A1 (fr) 2018-08-30
WO2018156801A2 (fr) 2018-08-30
EP3585420A2 (fr) 2020-01-01
EP4066850A2 (fr) 2022-10-05
EP4066850A3 (fr) 2022-11-23
CN110869044A (zh) 2020-03-06

Similar Documents

Publication Publication Date Title
EP3496666A4 (fr) Dispositifs et procédés pour le traitement d'une insuffisance valvulaire
EP3634430A4 (fr) Agents multibiotiques et procédés d'utilisation de ceux-ci
EP3538561A4 (fr) Polypeptides de variant guidés par arn et leurs procédés d'utilisation
EP3474785A4 (fr) Implant vertébral et ses procédés d'utilisation
EP3442991A4 (fr) Peptides de liaison à ras et méthodes d'utilisation
EP3720502A4 (fr) Produits cytobiologiques et leurs utilisations thérapeutiques
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
EP3684821A4 (fr) Anticorps anti-hla-a2 et leurs procédés d'utilisation
EP3478723A4 (fr) Anticorps spécifiques de pd-l1 et procédés pour les utiliser
EP3633034A4 (fr) PROTÉINE Cas9 MODIFIÉE, ET APPLICATION ASSOCIÉE
EP3635418A4 (fr) Appareil et procédés d'évaluation de coupure de courant
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3558279A4 (fr) Compositions et méthode s pour le traitement d'une douleur chronique
EP3525703A4 (fr) Dispositifs et procédés de traitement
ZA201905851B (en) Peptides and methods for the treatment of diabetes
EP3651747A4 (fr) Compositions et méthodes de traitement de troubles oculaires
EP3678701A4 (fr) Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3635000A4 (fr) Manabodies et procédés d'utilisation
EP3348273B8 (fr) Compositions à base de protéines et de xyloglucane pour le traitement de troubles intestinaux
EP3419425A4 (fr) Dispositifs de cuisson et leurs procédés d'utilisation
EP3429584A4 (fr) Compositions et méthodes de traitement de la presbytie
EP3377085A4 (fr) Peptides et méthodes de traitement de l'endométriose utilisant lesdits peptides
EP3258930A4 (fr) Oxabicycloheptanes et oxabicycloheptènes permettant de traiter des troubles dépressifs et de stress
EP3554626A4 (fr) Méthodes et dispositifs destinés au traitement de troubles d'origine vasculaire

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190917

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40021181

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/10 20060101ALI20201127BHEP

Ipc: A61K 45/06 20060101ALI20201127BHEP

Ipc: A61K 38/04 20060101ALI20201127BHEP

Ipc: A61K 38/17 20060101ALI20201127BHEP

Ipc: A61K 38/08 20190101ALI20201127BHEP

Ipc: A61P 21/00 20060101ALI20201127BHEP

Ipc: A61K 38/19 20060101AFI20201127BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210309

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/19 20060101AFI20210302BHEP

Ipc: A61K 38/10 20060101ALI20210302BHEP

Ipc: A61K 45/06 20060101ALI20210302BHEP

Ipc: A61K 38/17 20060101ALI20210302BHEP

Ipc: A61K 38/08 20190101ALI20210302BHEP

Ipc: A61K 38/04 20060101ALI20210302BHEP

Ipc: A61P 21/00 20060101ALI20210302BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220901